Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1998 Jul;82(7):810–815. doi: 10.1136/bjo.82.7.810

Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study

A Heiligenhaus 1, B Steinmetz 1, R Lapuente 1, P Krallmann 1, C Althaus 1, W Steinkamp 1, B Dick 1
PMCID: PMC1722665  PMID: 9924378

Abstract

AIMS—This study investigated the effect of tissue plasminogen activator (tPA) in patients with severe intracameral fibrin after extracapsular cataract extraction or phacoemulsification with posterior chamber intraocular lens implantation.
METHODS—A randomised prospective multicentre study was carried out in 86 patients with intraocular fibrin formation 2-8 days after cataract surgery. While the first group (n=41) received only anti-inflammatory drugs, a single anterior chamber injection of tPA (10 µg) as an additional treatment to the standard was given in the second group (n=44). On days 1, 2, 14, and 90 after randomisation, the visual acuities, slit lamp findings, and intraocular pressures were documented in standardised protocols. Efficacy of treatment was judged by the rate of fibrinolysis (primary objective), the frequency of synechiae, and central capsular fibrosis (secondary objectives).
RESULTS—The incidence and quantity of intraocular fibrin were significantly lower in the patients treated with tPA than in the control group (p<0.05). The frequencies of synechiae were reduced by tPA injection. The capsule fibrosis noted after 3 months was significantly lower in the tPA group (p=0.027). No ocular side effects were noted after the tPA injections.
CONCLUSIONS—Lysis of postcataract fibrin formation is accelerated and increased by a single intracameral injection of 10 µg tPA in addition to standard anti-inflammatory treatment. The findings suggest that the tPA injection reduces posterior capsule fibrosis, which still has to be addressed in larger study populations and with a long term follow up.

 Keywords: tissue plasminogen activator; cataract surgery; fibrin; fibrinolysis

Full Text

The Full Text of this article is available as a PDF (111.1 KB).

Figure 1  .

Figure 1  

Open in a new tab

Diagram showing the action of tissue plasminogen activator (tPA).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Apple D. J., Mamalis N., Loftfield K., Googe J. M., Novak L. C., Kavka-Van Norman D., Brady S. E., Olson R. J. Complications of intraocular lenses. A historical and histopathological review. Surv Ophthalmol. 1984 Jul-Aug;29(1):1–54. doi: 10.1016/0039-6257(84)90113-9. [DOI] [PubMed] [Google Scholar]
  2. Apple D. J., Solomon K. D., Tetz M. R., Assia E. I., Holland E. Y., Legler U. F., Tsai J. C., Castaneda V. E., Hoggatt J. P., Kostick A. M. Posterior capsule opacification. Surv Ophthalmol. 1992 Sep-Oct;37(2):73–116. doi: 10.1016/0039-6257(92)90073-3. [DOI] [PubMed] [Google Scholar]
  3. Collen D., Lijnen H. R. Tissue-type plasminogen activator. Mechanisms of action and thrombolytic properties. Haemostasis. 1986;16 (Suppl 3):25–32. doi: 10.1159/000215363. [DOI] [PubMed] [Google Scholar]
  4. Dabbs C. K., Aaberg T. M., Aguilar H. E., Sternberg P., Jr, Meredith T. A., Ward A. R. Complications of tissue plasminogen activator therapy after vitrectomy for diabetes. Am J Ophthalmol. 1990 Oct 15;110(4):354–360. doi: 10.1016/s0002-9394(14)77014-x. [DOI] [PubMed] [Google Scholar]
  5. Fagerholm P. P., Philipson B. T. Experimental traumatic cataract. II. A transmission electron microscopy and extracellular tracer study. Invest Ophthalmol Vis Sci. 1979 Nov;18(11):1160–1171. [PubMed] [Google Scholar]
  6. Fagerholm P. P. The response of the lens to trauma. Trans Ophthalmol Soc U K. 1982;102(Pt 3):369–374. [PubMed] [Google Scholar]
  7. Folk J. C., Hershey J. M., Rivers M. B. Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy. Arch Ophthalmol. 1991 May;109(5):614–614. doi: 10.1001/archopht.1991.01080050020010. [DOI] [PubMed] [Google Scholar]
  8. Fourman S., Wiley L. Tissue plasminogen activator modifies healing of glaucoma filtering surgery in rabbits. Ophthalmic Surg. 1991 Dec;22(12):718–723. [PubMed] [Google Scholar]
  9. Goodman D. F., Stark W. J., Gottsch J. D. Complications of cataract extraction with intraocular lens implantation. Ophthalmic Surg. 1989 Feb;20(2):132–140. [PubMed] [Google Scholar]
  10. Heiligenhaus A., Schilling H., Schilling M., Mellin K. B. Behandlung mit Gewebsplasminogenaktivator (tPA) bei Risikopatienten mit Fibrinreaktionen nach Kataraktoperationen. Ophthalmologe. 1996 Feb;93(1):49–53. [PubMed] [Google Scholar]
  11. Irvine W. D., Johnson M. W., Hernandez E., Olsen K. R. Retinal toxicity of human tissue plasminogen activator in vitrectomized rabbit eyes. Arch Ophthalmol. 1991 May;109(5):718–722. doi: 10.1001/archopht.1991.01080050134044. [DOI] [PubMed] [Google Scholar]
  12. Ishibashi T., Hatae T., Inomata H. Collagen types in human posterior capsule opacification. J Cataract Refract Surg. 1994 Nov;20(6):643–646. doi: 10.1016/s0886-3350(13)80655-4. [DOI] [PubMed] [Google Scholar]
  13. Jaffe G. J., Abrams G. W., Williams G. A., Han D. P. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990 Feb;97(2):184–189. doi: 10.1016/s0161-6420(90)32618-0. [DOI] [PubMed] [Google Scholar]
  14. Johnson R. N., Olsen K., Hernandez E. Tissue plasminogen activator treatment of postoperative intraocular fibrin. Ophthalmology. 1988 May;95(5):592–596. doi: 10.1016/s0161-6420(88)33140-4. [DOI] [PubMed] [Google Scholar]
  15. Koerner F., Boehnke M. Clinical use of recombinant plasminogen activator for intraocular fibrinolysis. Ger J Ophthalmol. 1992;1(5):354–360. [PubMed] [Google Scholar]
  16. Krupsky S., Zalish M., Oliver M., Pollack A. Anterior segment complications in diabetic patients following extracapsular cataract extraction and posterior chamber intraocular lens implantation. Ophthalmic Surg. 1991 Sep;22(9):526–530. [PubMed] [Google Scholar]
  17. Lim J. I., Fiscella R., Tessler H., Gagliano D. A., Chaques-Alepuz V., Mohler M. A. Intraocular penetration of topical tissue plasminogen activator. Arch Ophthalmol. 1991 May;109(5):714–717. doi: 10.1001/archopht.1991.01080050130043. [DOI] [PubMed] [Google Scholar]
  18. Lim J. I., Maguire A. M., John G., Mohler M. A., Fiscella R. G. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology. 1993 Mar;100(3):373–376. doi: 10.1016/s0161-6420(93)31639-8. [DOI] [PubMed] [Google Scholar]
  19. Little H. L. Alterations in blood elements in the pathogenesis of diabetic retinopathy. Ophthalmology. 1981 Jul;88(7):647–654. doi: 10.1016/s0161-6420(81)34971-9. [DOI] [PubMed] [Google Scholar]
  20. Lundy D. C., Sidoti P., Winarko T., Minckler D., Heuer D. K. Intracameral tissue plasminogen activator after glaucoma surgery. Indications, effectiveness, and complications. Ophthalmology. 1996 Feb;103(2):274–282. doi: 10.1016/s0161-6420(96)30704-5. [DOI] [PubMed] [Google Scholar]
  21. McDermott M. L., Edelhauser H. F., Hyndiuk R. A., Koenig S. B. Tissue plasminogen activator and the corneal endothelium. Am J Ophthalmol. 1989 Jul 15;108(1):91–92. doi: 10.1016/s0002-9394(14)73273-8. [DOI] [PubMed] [Google Scholar]
  22. McDonnell P. J., Zarbin M. A., Green W. R. Posterior capsule opacification in pseudophakic eyes. Ophthalmology. 1983 Dec;90(12):1548–1553. doi: 10.1016/s0161-6420(83)34350-5. [DOI] [PubMed] [Google Scholar]
  23. Miyake K., Asakura M., Kobayashi H. Effect of intraocular lens fixation on the blood-aqueous barrier. Am J Ophthalmol. 1984 Oct 15;98(4):451–455. doi: 10.1016/0002-9394(84)90130-2. [DOI] [PubMed] [Google Scholar]
  24. Moon J., Chung S., Myong Y., Chung S., Park C., Baek N., Rhee S. Treatment of postcataract fibrinous membranes with tissue plasminogen activator. Ophthalmology. 1992 Aug;99(8):1256–1259. doi: 10.1016/s0161-6420(92)31815-9. [DOI] [PubMed] [Google Scholar]
  25. Nishi O. Fibrinous membrane formation on the posterior chamber lens during the early postoperative period. J Cataract Refract Surg. 1988 Jan;14(1):73–77. doi: 10.1016/s0886-3350(88)80068-3. [DOI] [PubMed] [Google Scholar]
  26. Pennica D., Holmes W. E., Kohr W. J., Harkins R. N., Vehar G. A., Ward C. A., Bennett W. F., Yelverton E., Seeburg P. H., Heyneker H. L. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature. 1983 Jan 20;301(5897):214–221. doi: 10.1038/301214a0. [DOI] [PubMed] [Google Scholar]
  27. Rowland F. N., Donovan M. J., Gillies C., O'Rourke J., Kreutzer D. L. Fibrin: mediator of in vivo and in vitro injury and inflammation. Curr Eye Res. 1985 May;4(5):537–553. doi: 10.3109/02713688508999985. [DOI] [PubMed] [Google Scholar]
  28. Sebestyen J. G. Fibrinoid syndrome: a severe complication of vitrectomy surgery in diabetics. Ann Ophthalmol. 1982 Sep;14(9):853–856. [PubMed] [Google Scholar]
  29. Snyder R. W., Lambrou F. H., Williams G. A. Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. Arch Ophthalmol. 1987 Sep;105(9):1277–1280. doi: 10.1001/archopht.1987.01060090135044. [DOI] [PubMed] [Google Scholar]
  30. Steinert R. F., Puliafito C. A., Kumar S. R., Dudak S. D., Patel S. Cystoid macular edema, retinal detachment, and glaucoma after Nd:YAG laser posterior capsulotomy. Am J Ophthalmol. 1991 Oct 15;112(4):373–380. doi: 10.1016/s0002-9394(14)76242-7. [DOI] [PubMed] [Google Scholar]
  31. Sterling S., Wood T. O. Effect of intraocular lens convexity on posterior capsule opacification. J Cataract Refract Surg. 1986 Nov;12(6):655–657. doi: 10.1016/s0886-3350(86)80080-3. [DOI] [PubMed] [Google Scholar]
  32. Thorsen S., Glas-Greenwalt P., Astrup T. Differences in the binding to fibrin of urokinase and tissue plasminogen activator. Thromb Diath Haemorrh. 1972 Aug 31;28(1):65–74. [PubMed] [Google Scholar]
  33. Van de Werf F., Bergmann S. R., Fox K. A., de Geest H., Hoyng C. F., Sobel B. E., Collen D. Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. Circulation. 1984 Mar;69(3):605–610. doi: 10.1161/01.cir.69.3.605. [DOI] [PubMed] [Google Scholar]
  34. Vidaurri-Leal J. S., Glaser B. M. Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol. 1984 Sep;102(9):1376–1379. doi: 10.1001/archopht.1984.01040031118037. [DOI] [PubMed] [Google Scholar]
  35. Wedrich A., Menapace R., Mühlbauer-Ries E. The use of recombinant tissue plasminogen activator for intracameral fibrinolysis following cataract surgery. Int Ophthalmol. 1994;18(5):277–280. doi: 10.1007/BF00917830. [DOI] [PubMed] [Google Scholar]
  36. Wilhelmus K. R., Emery J. M. Posterior capsule opacification following phacoemulsification. Ophthalmic Surg. 1980 Apr;11(4):264–267. [PubMed] [Google Scholar]
  37. Williams D. F., Bennett S. R., Abrams G. W., Han D. P., Mieler W. F., Jaffe G. J., Williams G. A. Low-dose intraocular tissue plasminogen activator for treatment of postvitrectomy fibrin formation. Am J Ophthalmol. 1990 May 15;109(5):606–607. doi: 10.1016/s0002-9394(14)70700-7. [DOI] [PubMed] [Google Scholar]
  38. Williams G. A., Lambrou F. H., Jaffe G. A., Snyder R. W., Green G. D., Devenyi R. G., Abrams G. W. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 1988 Aug;106(8):1055–1058. doi: 10.1001/archopht.1988.01060140211025. [DOI] [PubMed] [Google Scholar]
  39. Wollensak G., Meyer J. H., Löffler K. U., Funk J. Bandförmige Keratopathie nach Behandlung der postoperativen Fibrinreaktion mit Gewebeplasminogenaktivator. Klin Monbl Augenheilkd. 1996 Jul;209(1):43–46. doi: 10.1055/s-2008-1035276. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES